The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design

BMC Microbiology

Volumn 11, Issue , 2011, Pages

  Im, Hookang ^a   Sharpe, Miriam L ^b   Strych, Ulrich ^c   Davlieva, Milya ^d   Krause, Kurt L ^b  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c University of Houston   (United States)

^d RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE RACEMASE; BACTERIAL ENZYME;

AMINO TERMINAL SEQUENCE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIMERIZATION; ENZYME INACTIVATION; GENE OVEREXPRESSION; GRAM POSITIVE BACTERIUM; HYDROGEN BOND; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RACEMIZATION; REVIEW; STREPTOCOCCUS PNEUMONIAE; X RAY DIFFRACTION; AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYMOLOGY; HUMAN; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

ALANINE RACEMASE; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; STREPTOCOCCUS PNEUMONIAE;

EID: 80055068595     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-11-116     Document Type: Review

References (78)

1. Medicine in the Nineteenth Century. SW Osler, Aequanimitas: with other addresses to medical students, nurses and and practitioners of medicine Philadelphia: P. Blakiston's Son & Co 1905 217 262
2. Pneumococcal virulence factors: structure and function. MJ Jedrzejas, Microbiol Mol Biol Rev 2001 65 187 207 10.1128/MMBR.65.2.187-207.2001 11381099 (Pubitemid 32538177)
3. Antibiotics in childhood pneumonia. KA Hale D Isaacs, Paediatr Respir Rev 2006 7 145 151 10.1016/j.prrv.2006.03.011 16765302 (Pubitemid 43812271)
4. Acute Respiratory Infections (Update September 2009). World Health Organization Initiative for Vaccine Research, http://www.who.int/vaccine- research/diseases/ari/en/
5. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. KL O'Brien LJ Wolfson JP Watt E Henkle M Deloria-Knoll N McCall E Lee K Mulholland OS Levine T Cherian, Lancet 2009 374 893 902 10.1016/S0140-6736(09)61204-6 19748398
6. Antibiotic resistance. JG Bartlett JW Froggatt, Arch Otolaryngol Head Neck Surg 1995 121 392 396 7702812
7. Community-acquired pneumonia. TM File, Lancet 2003 362 1991 2001 10.1016/S0140-6736(03)15021-0 14683661
8. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. JF Brundage, Lancet Infect Dis 2006 6 303 312 10.1016/S1473-3099(06)70466-2 16631551
9. Pneumococcal vaccines and flu preparedness. KP Klugman SA Madhi, Science 2007 316 49 50 17412937
10. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. G Palacios M Hornig D Cisterna N Savji AV Bussetti V Kapoor J Hui R Tokarz T Briese E Baumeister WI Lipkin, PLoS ONE 2009 4 8540 10.1371/journal.pone.0008540 20046873
11. Prevalence of penicillin-resistant pneumococci in Houston, Texas. KL Krause C Stager LO Gentry, Am J Clin Pathol 1982 77 210 213 7064918 (Pubitemid 12162501)
12. Streptococcus pneumoniae: does antimicrobial resistance matter? JP Lynch GG Zhanel, Semin Respir Crit Care Med 2009 30 210 238 10.1055/s-0029-1202939 19296420
13. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. DA Watson DM Musher JW Jacobson J Verhoef, Clin Infect Dis 1993 17 913 924 10.1093/clinids/17.5.913 8286641 (Pubitemid 23321919)
14. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. TM File Jr, Clin Microbiol Infect 2006 12 Suppl 3 31 41 16669927
15. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. MR Jacobs D Felmingham PC Appelbaum RN Gruneberg, J Antimicrob Chemother 2003 52 229 246 10.1093/jac/dkg321 12865398 (Pubitemid 36986885)
16. The antimicrobial resistance profile of Streptococcus pneumoniae. RR Reinert, Clin Microbiol Infect 2009 15 Suppl 3 7 11 19366363
17. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). DJ Farrell C Couturier W Hryniewicz, Int J Antimicrob Agents 2008 31 245 249 10.1016/j.ijantimicag.2007.10.022 18178388
18. Factors affecting the level of alanine racemase in Escherichia coli. MP Lambert FC Neuhaus, J Bacteriol 1972 109 1156 1161 4551748
19. The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. DL Milligan SL Tran U Strych GM Cook KL Krause, J Bacteriol 2007 189 8381 8386 10.1128/JB.01201-07 17827284 (Pubitemid 350178954)
20. Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth. O Chacon Z Feng NB Harris NE Caceres LG Adams RG Barletta, Antimicrob Agents Chemother 2002 46 47 54 10.1128/AAC.46.2.47-54.2002 11751110 (Pubitemid 34031601)
21. Purification and preliminary crystallization of alanine racemase from Streptococcus pneumoniae. U Strych M Davlieva J Longtin E Murphy H Im M Benedik K Krause, BMC Microbiol 2007 7 40 10.1186/1471-2180-7-40 17509154
22. The potential use of mechanism-based enzyme inactivators in medicine. RB Silverman, J Enzyme Inhib 1988 2 73 90 10.3109/14756368809040714 3069967 (Pubitemid 18033735)
23. Three dimensional structure-aided drug design. B Veerapandian, Burger's Medicinal Chemistry and Drug Discovery Volume 1 New York: John Wiley & Sons, Inc, Wolff ME, 5 1995 303 348 21611913
24. Structure-based drug design: computational advances. TJ Marrone JM Briggs JA McCammon, Annu Rev Pharmacol Toxicol 1997 37 71 90 10.1146/annurev.pharmtox. 37.1.71 9131247 (Pubitemid 27238870)
25. Structure-based drug design. TL Blundell, Nature 1996 384 23 26 10.1038/384023a0 8900268 (Pubitemid 26374536)
26. Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase. TD Fenn T Holyoak GF Stamper D Ringe, Biochemistry 2005 44 5317 5327 10.1021/bi047842l 15807525 (Pubitemid 40489971)
27. A side reaction of alanine racemase: transamination of cycloserine. TD Fenn GF Stamper AA Morollo D Ringe, Biochemistry 2003 42 5775 5783 10.1021/bi027022d 12741835 (Pubitemid 36582869)
28. Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase. AA Morollo GA Petsko D Ringe, Biochemistry 1999 38 3293 3301 10.1021/bi9822729 10079072
29. Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9- resolution. JP Shaw GA Petsko D Ringe, Biochemistry 1997 36 1329 1342 10.1021/bi961856c 9063881 (Pubitemid 27074957)
30. Reaction of alanine racemase with 1-aminoethylphosphonic acid forms a stable external aldimine. GF Stamper AA Morollo D Ringe, Biochemistry 1998 37 10438 10445 10.1021/bi980692s 9671513 (Pubitemid 28357566)
31. Reaction mechanism of alanine racemase from Bacillus stearothermophilus. A Watanabe T Yoshimura B Mikami H Hayashi H Kagamiyama N Esaki, J Biol Chem 2002 277 19166 19172 10.1074/jbc.M201615200 11886871
32. Crystal structure at 1.45 resolution of alanine racemase from a pathogenic bacterium, Pseudomonas aeruginosa, contains both internal and external aldimine forms. P LeMagueres H Im A Dvorak U Strych M Benedik KL Krause, Biochemistry 2003 42 14752 14761 10.1021/bi030165v 14674749 (Pubitemid 37553503)
33. Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product. M Noda Y Matoba T Kumagai M Sugiyama, J Biol Chem 2004 279 46153 46161 10.1074/jbc.M404605200 15302886 (Pubitemid 39491610)
34. The 1.9 crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. P LeMagueres H Im J Ebalunode U Strych MJ Benedik JM Briggs H Kohn KL Krause, Biochemistry 2005 44 1471 1481 10.1021/bi0486583 15683232 (Pubitemid 40204391)
35. Structures of an alanine racemase from Bacillus anthracis (BA0252) in the presence and absence of (R)-1-aminoethylphosphonic acid (l-Ala-P). K Au J Ren TS Walter K Harlos JE Nettleship RJ Owens DI Stuart RM Esnouf, Acta Crystallogr Sect F Struct Biol Cryst Commun 2008 64 327 333 10.1107/S1744309108007252 18453697 (Pubitemid 351631214)
36. Biochemical and structural characterization of alanine racemase from Bacillus anthracis (Ames). R Coũago M Davlieva U Strych R Hill K Krause, BMC Struct Biol 2009 9 53 10.1186/1472-6807-9-53 19695097
37. Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from E. coli: Enzymatic characterization with crystal structure analysis. D Wu T Hu L Zhang J Chen J Du J Ding H Jiang X Shen, Protein Sci 2008 17 1066 1076 10.1110/ps.083495908 18434499 (Pubitemid 351749212)
38. Structural insights into the alanine racemase from Enterococcus faecalis. A Priyadarshi EH Lee MW Sung KH Nam WH Lee EE Kim KY Hwang, Biochim Biophys Acta 2009 1794 1030 1040 19328247
39. A model for enzyme-substrate interaction in alanine racemase. MJ Ondrechen JM Briggs JA McCammon, J Am Chem Soc 2001 123 2830 2834 10.1021/ja0029679 11456969 (Pubitemid 32910708)
40. Tyrosine 265 of alanine racemase serves as a base abstracting alpha-hydrogen from L-alanine: the counterpart residue to lysine 39 specific to D-alanine. A Watanabe T Yoshimura B Mikami N Esaki, J Biochem 1999 126 781 786 10502689 (Pubitemid 29500401)
41. Evidence for a two-base mechanism involving tyrosine-265 from arginine-219 mutants of alanine racemase. S Sun MD Toney, Biochemistry 1999 38 4058 4065 10.1021/bi982924t 10194319
42. Crystallography & NMR system: A new software suite for macromolecular structure determination. AT Brunger PD Adams GM Clore WL DeLano P Gros RW Grosse-Kunstleve JS Jiang J Kuszewski M Nilges NS Pannu,, et al. Acta Crystallogr D Biol Crystallogr 1998 54 905 921 10.1107/S0907444998003254 9757107
43. On the rigid-body motion of molecules in crystals. V Schomaker KN Trueblood, Acta Crystallogr B 1968 24 63 76 10.1107/S0567740868001718
44. The CCP4 Suite: Programs for Protein Crystallography. Collaborative Computational Project Number 4, Acta Crystallogr D Biol Crystallogr 1994 50 760 763 10.1107/S0907444994003112 15299374
45. PROCHECK: a program to check the stereochemical quality of protein structures. RA Laskowski MW MacArthur DS Moss JM Thornton, J Appl Crystallogr 1993 26 283 291 10.1107/S0021889892009944
46. Databases in protein crystallography. GJ Kleywegt TA Jones, Acta Crystallogr D Biol Crystallogr 1998 54 1119 1131 10.1107/S0907444998007100 10089488 (Pubitemid 29000167)
47. Mutant analysis shows that alanine racemases from Pseudomonas aeruginosa and Escherichia coli are dimeric. U Strych MJ Benedik, J Bacteriol 2002 184 4321 4325 10.1128/JB.184.15.4321-4325.2002 12107154 (Pubitemid 34774317)
48. Subunit interaction of monomeric alanine racemases from four Shigella species in catalytic reaction. K Yokoigawa Y Okubo K Soda, FEMS Microbiol Lett 2003 221 263 267 10.1016/S0378-1097(03)00216-7 12725937 (Pubitemid 41123073)
49. Correlation between catalytic activity and monomer-dimer equilibrium of bacterial alanine racemases. J Ju S Xu Y Furukawa Y Zhang H Misono T Minamino K Namba B Zhao K Ohnishi, J Biochem 2011 149 83 89 10.1093/jb/mvq120 20971724
50. Alanine racemase free energy profiles from global analyses of progress curves. MA Spies JJ Woodward MR Watnik MD Toney, J Am Chem Soc 2004 126 7464 7475 10.1021/ja049579h 15198593 (Pubitemid 38781480)
51. Site-directed mutagenesis of Tyr354 in Geobacillus stearothermophilus alanine racemase identifies a role in controlling substrate specificity and a possible role in the evolution of antibiotic resistance. WM Patrick J Weisner JM Blackburn, Chembiochem 2002 3 789 792 10.1002/1439-7633(20020802)3:8<789:: AID-CBIC7893.0.CO;2-D 12203980 (Pubitemid 36004521)
52. On the function of the 14 long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. DF Wang O Wiest P Helquist HY Lan-Hargest NL Wiech, J Med Chem 2004 47 3409 3417 10.1021/jm0498497 15189037 (Pubitemid 38746091)
53. Dimerization inhibitors of HIV-1 protease. N Boggetto M Reboud-Ravaux, Biol Chem 2002 383 1321 1324 10.1515/BC.2002.150 12437124 (Pubitemid 35282949)
54. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. M Song S Rajesh Y Hayashi Y Kiso, Bioorg Med Chem Lett 2001 11 2465 2468 10.1016/S0960-894X(01)00468-1 11549448 (Pubitemid 32823335)
55. Breaking the spell: drug discovery based on modulating protein-protein interactions. AD Strosberg, Expert Rev Proteomics 2004 1 141 143 10.1586/14789450.1.2.141 15966807
56. A common allosteric site and mechanism in caspases. JM Scheer MJ Romanowski JA Wells, Proc Natl Acad Sci USA 2006 103 7595 7600 10.1073/pnas.0602571103 16682620
57. Cluster analysis of water molecules in alanine racemase and their putative structural role. G Mustata JM Briggs, Protein Eng Des Sel 2004 17 223 234 10.1093/protein/gzh033 15115851 (Pubitemid 38781194)
58. Water structure of a hydrophobic protein at atomic resolution: Pentagon rings of water molecules in crystals of crambin. MM Teeter, Proc Natl Acad Sci USA 1984 81 6014 6018 10.1073/pnas.81.19.6014 16593516
59. Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. L Weinstein, The pharmacological basis of therapeutics New York: Macmillan Publishing Co. Inc, Goodman LS,Gilman A, 5 1975 1201 1223
60. A structure-based design approach for the identification of novel inhibitors: application to an alanine racemase. GI Mustata JM Briggs, J Comput Aided Mol Des 2002 16 935 953 10.1023/A:1023875514454 12825624 (Pubitemid 36701527)
61. The structure of mammalian serine racemase: evidence for conformational changes upon inhibitor binding. MA Smith V Mack A Ebneth I Moraes B Felicetti M Wood D Schonfeld O Mather A Cesura J Barker, J Biol Chem 2010 285 12873 12881 10.1074/jbc.M109.050062 20106978
62. C Walsh, Antibiotics: Actions, origins, resistance Washington, DC: American Society for Microbiology Press 2003
63. Processing of X-ray diffraction data collected in oscillation mode. Z Otwinowski W Minor, Methods Enzymol 1997 276 307 326 (Pubitemid 27085611)
64. Solvent content of protein crystals. BW Matthews, J Mol Biol 1968 33 491 497 10.1016/0022-2836(68)90205-2 5700707
65. Automated refinement for protein crystallography. VS Lamzin KS Wilson, Methods Enzymol 1997 277 269 305 18488314 (Pubitemid 27390926)
66. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. J Painter EA Merritt, Acta Crystallogr D Biol Crystallogr 2006 62 439 450 10.1107/S0907444906005270 16552146
67. TLSMD web server for the generation of multi-group TLS models. J Painter EA Merritt, J Appl Crystallogr 2006 39 109 111 10.1107/S0021889805038987
68. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. E Krissinel K Henrick, Acta Crystallogr D Biol Crystallogr 2004 60 2256 2268 10.1107/S0907444904026460 15572779 (Pubitemid 41742778)
69. Inference of macromolecular assemblies from crystalline state. E Krissinel K Henrick, J Mol Biol 2007 372 774 797 10.1016/j.jmb.2007.05.022 17681537 (Pubitemid 47321791)
70. ProtorP: a protein-protein interaction analysis server. C Reynolds D Damerell S Jones, Bioinformatics 2009 25 413 414 10.1093/bioinformatics/btn584 19001476
71. The PyMOL Molecular Graphics System. WL DeLano, http://www.pymol.org/
72. Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. AM Waterhouse JB Procter DM Martin M Clamp GJ Barton, Bioinformatics 2009 25 1189 1191 10.1093/bioinformatics/btp033 19151095
73. Electrostatics of nanosystems: application to microtubules and the ribosome. NA Baker D Sept S Joseph MJ Holst JA McCammon, Proc Natl Acad Sci USA 2001 98 10037 10041 10.1073/pnas.181342398 11517324 (Pubitemid 32802969)
74. PDB 2PQR : an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. TJ Dolinsky JE Nielsen JA McCammon NA Baker, Nucleic Acids Res 2004 32 665 667 10.1093/nar/gkh381 15215472
75. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. AW Schuttelkopf DM van Aalten, Acta Crystallogr D Biol Crystallogr 2004 60 1355 1363 10.1107/S0907444904011679 15272157 (Pubitemid 41079731)
76. Thermostable alanine racemase from Bacillus stearothermophilus: molecular cloning of the gene, enzyme purification, and characterization. K Inagaki K Tanizawa B Badet CT Walsh H Tanaka K Soda, Biochemistry 1986 25 3268 3274 10.1021/bi00359a028 3015202 (Pubitemid 16056969)
77. A novel assay method for an amino acid racemase reaction based on circular dichroism. M Noda Y Matoba T Kumagai M Sugiyama, Biochem J 2005 389 491 496 10.1042/BJ20041649 15796715 (Pubitemid 41021153)
78. Purification of an alanine racemase from Streptococcus faecalis and analysis of its inactivation by (1-aminoethyl)phosphonic acid enantiomers. B Badet C Walsh, Biochemistry 1985 24 1333 1341 10.1021/bi00327a010 3921052 (Pubitemid 15091390)